# psoriasis - claude-opus-4-8

- Benchmark system: E2seq + Agent RAG
- Repeat: 1
- Task type: DISEASE-STATE
- Tissue / sample source: lesional skin
- Comparison or endpoint: psoriatic lesional skin versus normal control skin
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: Anthropic / claude-opus-4-8
- Message SHA-256: d1a33d3f606c81814c4fb94a6c63c8f1abebd3bde37d769e82eae4772d8ff873
- Response HTTP status: 200
- Prompt tokens: 18093
- Completion tokens: 6744
- Reasoning tokens: 0
- Total tokens: 24837
- API requests reported: 2
- Elapsed seconds: 295.669
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 1150.303
- Question handoff seconds: 1163.566
- Final benchmark system: E2seq; file rank 1/5; original repeat 1; model vendor: Anthropic

---
# Multidimensional Interpretation of Psoriatic Lesional Skin Transcriptomics

## 1. Overall Biological Interpretation

The transcriptomic profile of psoriatic lesional skin reveals a coordinated hyperactivation of inflammatory and epithelial defense programs characteristic of immune-mediated barrier disease. The data shows 90 upregulated genes with extreme effect sizes (log2FC ranging from 1.86 to 11.37) against only 10 downregulated genes, indicating profound transcriptional activation rather than a balanced regulatory shift.

Three converging biological themes dominate: (1) IL-17/IL-36 cytokine axis activation driving keratinocyte hyperproliferation and antimicrobial peptide production, (2) aberrant epidermal differentiation with premature cornification program activation, and (3) sustained innate immune signaling with neutrophil and T-cell recruitment chemokines. The molecular signature represents not simply inflammation added to normal skin, but a fundamentally altered epithelial state where barrier cells function as active immune effectors.

The pattern is internally consistent across pathway enrichment (IL-17 signaling, antimicrobial response, epidermis development), protein networks (SPRR/LCE cornification clusters, defensin/S100A antimicrobial clusters), and individual gene magnitudes (IL36A log2FC=11.37, DEFB4A/4B log2FC>11). This coherence, combined with uniform statistical significance (all FDR<0.01), indicates a stable disease-state transcriptional program rather than heterogeneous or transient responses.

---

## 2. Core Biological Programs

### **Program 1: IL-17/IL-36 Cytokine Amplification Loop**

**Direction:** Strongly upregulated

**Major supporting genes:**  
- IL36A (log2FC=11.37), IL36G (log2FC=5.68), IL36RN (log2FC=3.01)
- IL19 (log2FC=7.58), IL20 (log2FC=5.67) — IL-20 subfamily members
- TNIP3 (log2FC=7.28) — negative regulator paradoxically upregulated
- ZC3H12A (log2FC=3.85) — mRNA decay factor in IL-17 signaling

**Pathway:** KEGG IL-17 signaling pathway; Reactome Interleukin-17 signaling

**Evidence:**  
IL-36 cytokines are keratinocyte-derived IL-1 family members that amplify IL-17-driven inflammation in psoriasis. IL36A and IL36G encode agonists while IL36RN encodes the receptor antagonist; their concurrent upregulation reflects both amplification and attempted counter-regulation. IL19 and IL20, downstream of IL-17, promote keratinocyte proliferation and chemokine production. TNIP3 normally restricts NFκB signaling but its upregulation here may reflect feedback induction rather than effective suppression. ZC3H12A degrades inflammatory transcripts but is itself IL-17-induced, creating regulatory complexity.

The collective pattern—multiple IL-36 ligands, IL-20 subfamily cytokines, and pathway regulators all upregulated—indicates an active, self-reinforcing cytokine network rather than a simple receptor-ligand activation. Network analysis confirms IL1RAP connections to IL36A/IL36G, supporting functional receptor complex formation.

**Strength and limitations:**  
Evidence is strong based on multiple independent cytokine genes with extreme effect sizes, established pathway enrichment, and known psoriasis biology. Limitation: the concurrent upregulation of negative regulators (IL36RN, TNIP3) complicates interpretation of net pathway activity; these could represent failed homeostatic feedback or be insufficient to overcome agonist excess. IL36RN shows moderate upregulation (log2FC=3.01) compared to agonists IL36A (log2FC=11.37) and IL36G (log2FC=5.68), suggesting the antagonist response is quantitatively inadequate to suppress pathway activation. Functional validation would require measuring protein levels and receptor occupancy rather than mRNA alone.

---

### **Program 2: Antimicrobial Peptide Defense Response**

**Direction:** Strongly upregulated

**Major supporting genes:**  
- DEFB4A (log2FC=11.18), DEFB4B (log2FC=11.03), DEFB103A (log2FC=5.76), DEFB103B (log2FC=5.75)
- S100A12 (log2FC=8.33), S100A7/S100A7A (network-connected)
- PI3 (log2FC=9.24) — elafin protease inhibitor
- TCN1 (log2FC=8.04) — antimicrobial transcobalamin

**Pathway:** GO Antimicrobial humoral response (GO:0019730); KEGG Staphylococcus aureus infection

**Evidence:**  
Four defensin genes show concordant massive upregulation, representing both β-defensin 2 (DEFB4A/4B) and β-defensin 3 (DEFB103A/B). These are among the most potent antimicrobial peptides in human skin, induced by IL-17 and IL-22 signaling. S100A12 and S100A7 are alarmin proteins with antimicrobial activity that also amplify inflammation through receptor engagement (RAGE, TLR4). PI3 inhibits neutrophil elastase while possessing direct antimicrobial function.

The coordinated upregulation of multiple independent antimicrobial families (defensins, S100A alarmins, protease inhibitors) indicates a broad-spectrum host defense activation. STRING network analysis confirms S100A7 hub connectivity to defensins and SERPINs. The magnitude of induction (log2FC>8 for multiple genes) exceeds typical acute infection responses, suggesting sustained pathway activation.

**Pathway enrichment for "Staphylococcus aureus infection" reflects the antimicrobial gene set rather than active infection in the samples.**

**Strength and limitations:**  
Evidence is strong with multiple gene families, network clustering, and pathway support. Antimicrobial peptide overproduction is a validated psoriasis feature and therapeutic target. Limitation: mRNA levels may overestimate functional antimicrobial activity, as peptide processing, secretion, and local concentration matter for efficacy. The biological purpose—whether antimicrobial defense against dysbiotic colonization or pathologic immune activation—cannot be distinguished from expression data alone.

---

### **Program 3: Aberrant Epidermal Differentiation and Cornification**

**Direction:** Upregulated

**Major supporting genes:**  
- SPRR2A (log2FC=7.31), SPRR2B (log2FC=6.38), SPRR2D (log2FC=5.92), SPRR2E (log2FC=3.99), SPRR3 (log2FC=7.18)
- LCE3A, LCE3D (network-connected to SPRR family)
- KRT6A (log2FC=4.30) — stress keratin
- KLK13 (log2FC=4.05) — kallikrein protease involved in desquamation

**Pathway:** GO Epidermis development (GO:0008544); Reactome Formation of the cornified envelope (R-HSA-6809371)

**Evidence:**  
Small proline-rich repeat (SPRR) proteins crosslink into the cornified envelope during terminal keratinocyte differentiation. Five SPRR2 family members and SPRR3 show concordant upregulation, indicating premature or dysregulated cornification program activation. Late cornified envelope (LCE) proteins cluster with SPRRs in STRING networks. KRT6A is a type II stress keratin induced in hyperproliferative epidermis, replacing the normal differentiation keratins.

The collective signal represents not simply "more differentiation" but an altered differentiation program. Normal epidermis expresses SPRR1 and LCE1 family members; psoriatic skin shifts to SPRR2/3 and LCE3 expression. This molecular switch, combined with KRT6A hyperproliferation marker and KLK13 desquamation protease, indicates the characteristic psoriatic epidermal phenotype: rapid transit from basal to cornified layers with abnormal protein composition.

Pathway enrichment specifically highlights "Formation of the cornified envelope" with 12 genes, supporting coordinated program activation rather than scattered individual gene changes.

**Strength and limitations:**  
Evidence is strong based on multiple SPRR family members, network clustering, specific pathway enrichment, and consistency with known psoriasis histology (parakeratosis, acanthosis). Limitation: SPRR expression is a terminal differentiation marker; the data does not reveal whether dysregulation occurs at the basal proliferation stage, early differentiation commitment, or terminal execution. The boundary between adaptive response to inflammation and primary differentiation defect cannot be resolved without temporal or perturbation studies.

---

### **Program 4: Lipid and Xenobiotic Metabolism Reprogramming**

**Direction:** Upregulated (with selective downregulation)

**Major supporting genes:**  
- AKR1B10 (log2FC=6.27), AKR1B15 (log2FC=5.23) — aldo-keto reductases
- FABP5 (log2FC=3.65) — fatty acid binding protein
- CYP2W1 (log2FC=-4.70, downregulated)
- KYNU (log2FC=4.42) — kynurenine pathway enzyme
- PLA2G4D (log2FC=4.62) — phospholipase A2

**Pathway:** Retinol metabolism, arachidonic acid metabolism (inferred from gene functions)

**Evidence:**  
AKR1B10 and AKR1B15 are aldo-keto reductases that metabolize retinaldehyde and lipid aldehydes, affecting retinoid signaling and oxidative stress responses. Their upregulation may deplete all-trans-retinal needed for retinoic acid synthesis, potentially disrupting retinoid-dependent keratinocyte differentiation. FABP5 shuttles fatty acids to PPARβ/δ in the nucleus; its upregulation can shift keratinocytes from differentiation-promoting retinoic acid signaling to proliferation-promoting PPAR signaling.

CYP2W1 downregulation (one of the few downregulated genes) is notable given that cytochrome P450s metabolize both xenobiotics and endogenous lipids. KYNU converts kynurenine to anthranilic acid in tryptophan metabolism; upregulation may reflect interferon-gamma-induced IDO1 pathway activation. PLA2G4D releases arachidonic acid for eicosanoid synthesis, contributing to inflammatory lipid mediator production.

The pattern suggests metabolic reprogramming affecting differentiation signaling (retinoids), inflammatory mediators (eicosanoids), and immune modulation (kynurenine pathway), rather than a single canonical pathway.

**Strength and limitations:**  
Evidence is moderate. Multiple metabolic enzymes show coordinated regulation and their functions are mechanistically plausible in psoriasis pathogenesis. AKR1B10 is validated in other hyperproliferative disorders. However, the evidence is more inferential than for cytokine or antimicrobial programs. Enzymatic activity and substrate/product levels are not measured. The functional impact of AKR1B10 upregulation on retinoid homeostasis in psoriatic skin is not directly demonstrated in this dataset. Metabolomic validation would strengthen interpretation.

---

### **Program 5: Chemokine-Mediated Leukocyte Recruitment**

**Direction:** Upregulated

**Major supporting genes:**  
- CXCL13 (log2FC=5.89) — B cell chemoattractant
- GPR15LG (log2FC=5.52) — T cell chemoattractant ligand for GPR15
- WNT5A (log2FC=2.53) — non-canonical Wnt with chemotactic properties
- HRH2 (log2FC=3.27) — histamine receptor H2

**Pathway:** KEGG Cytokine-cytokine receptor interaction; GO Response to lipopolysaccharide (GO:0032496, as proxy for immune cell recruitment context)

**Evidence:**  
CXCL13 is the defining chemokine for B cell follicle organization and is elevated in psoriatic skin, where ectopic lymphoid structures can form. GPR15LG is a skin-specific chemokine that recruits GPR15+ T cells to inflamed epithelia. WNT5A, beyond developmental roles, promotes macrophage and dendritic cell migration in inflammatory contexts. HRH2 mediates histamine signaling that modulates T cell and dendritic cell function.

These genes collectively support leukocyte recruitment and positioning, though the program is less prominent than cytokine amplification or antimicrobial defense (fewer genes, smaller effect sizes). CXCL13 upregulation specifically suggests adaptive immune organization beyond simple innate inflammation.

**Strength and limitations:**  
Evidence is moderate. Chemokine upregulation is expected in psoriasis and supported by pathway enrichment (cytokine-cytokine receptor interaction). However, the program is supported by fewer independent genes compared to the top three programs. CXCL13 is a strong individual marker, but broader chemokine family representation (CCL20, CXCL1/2/8) would strengthen the case for a major chemokine program. The dataset may underrepresent chemokines, or they may be less transcriptionally regulated (secreted protein effects not captured by mRNA). The functional consequence—actual immune cell infiltrate composition—cannot be inferred from epithelial transcriptomics alone.

---

## Summary

The five programs represent distinct but interconnected axes of psoriatic pathobiology: cytokine amplification, antimicrobial defense, epithelial differentiation, metabolic reprogramming, and leukocyte recruitment. The first three are strongly supported by multiple genes, extreme effect sizes, pathway clustering, and validation in psoriasis literature. The latter two are plausible but rest on fewer genes or more indirect evidence.

The overall transcriptional state reflects keratinocytes functioning as active immune participants rather than passive targets, consistent with psoriasis as an epithelial-immune interface disease. The extreme upregulation bias (90 vs 10 genes) and statistical uniformity (all FDR<0.01) indicate a stable, coordinated disease state rather than stochastic inflammation.

**Key evidence gaps:** (1) no independent cohort validation provided; (2) mRNA levels do not confirm protein function, post-translational regulation, or cellular localization; (3) directionality of causation (primary vs reactive changes) cannot be established from cross-sectional disease-state comparison; (4) the dataset represents bulk tissue, obscuring cell-type-specific contributions from keratinocytes, immune cells, and fibroblasts.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=32, external claims checked=0, external mismatches=0, status=passed.

Answer model API: Anthropic / claude-opus-4-8

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 91/100 selected items (records returned); cbioportal 91/100 selected items (records returned); chembl 11/100 selected items (partially returned; some queries failed); civic 4/100 selected items (records returned); clinicaltrials 40/100 selected items (records returned); clinvar 90/100 selected items (records returned); ensembl 44/100 selected items (partially returned; some queries failed); europepmc 848 articles / initial full-cohort RAG 100 queries + 4 current-round queries; gtex 83/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 76/100 selected items (records returned); humanbase 100/100 selected items (records returned); intact 79/100 selected items (records returned); mygene 100/100 selected items (records returned); omnipath 36/100 selected items (records returned); opentargets 90/100 selected items (records returned); pubmed 669 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 80/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 80/100 selected items (records returned)
Local databases: gutmgene 2/100 selected items (records returned); hmdb 25/100 selected items (records returned); string 78/100 selected items (records returned); trrust 17/100 selected items (records returned)
